We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · April 12, 2021

Valganciclovir Safe and Well-Tolerated in Patients With Idiopathic Pulmonary Fibrosis

Annals of the American Thoracic Society


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of the American Thoracic Society
A Phase I Randomized, Controlled Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis
Ann Am Thorac Soc 2021 Mar 19;[EPub Ahead of Print], TS Blackwell, JC Hewlett, WR Mason, S Martin, J Del Greco, G Ding, P Wu, LH Lancaster, JE Loyd, RB Dudenhofer, ML Salisbury, JA Kropski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading